guardanthealth.com (GH): שווי פעילות לרווח לפני ריבית, מסים ופחת

The EV/EBITDA valuation trend reflects the volatility of Guardant Health, Inc. (GH), which is burdened by debt and a lack of profitability amid its struggle for FDA approval. The business is currently transforming its strategy, shifting from recurrence monitoring to mass early screening. Meanwhile, the 0.00 metric indicates the maturity status of the asset, which strictly adheres to environmental regulations for biomaterial disposal.

This indicator measures the total enterprise value including net debt relative to operating profit, allowing for an assessment of the real value of assets without the influence of tax distortions. By analyzing the business valuation level via the EV/EBITDA multiple on the GURU.Markets platform, an investor can see the financing efficiency of Guardant Health (GH) in developing liquid biopsy for cancer diagnostics and clinical research for biopharmaceutical companies.